EMA/PE/0000183220
Submitted by Anonymous (not verified) on 10 December 2025 - 15:00
EMA/PE/0000183220
EMEA-002944-PIP01-20
Submitted by Anonymous (not verified) on 10 December 2025 - 14:58
EMEA-002944-PIP01-20
EMEA-003104-PIP02-22
Submitted by Anonymous (not verified) on 10 December 2025 - 14:56
EMEA-003104-PIP02-22
EMEA-002979-PIP01-21
Submitted by Anonymous (not verified) on 10 December 2025 - 14:54
EMEA-002979-PIP01-21
EMEA-001613-PIP04-21
Submitted by Anonymous (not verified) on 10 December 2025 - 14:52
EMEA-001613-PIP04-21
EMEA-001758-PIP01-15-M02
Submitted by Anonymous (not verified) on 10 December 2025 - 14:50
EMEA-001758-PIP01-15-M02
Human medicines European public assessment report (EPAR): Aimovig, erenumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 10 December 2025 - 14:48
Human medicines European public assessment report (EPAR): Aimovig, erenumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised
Human medicines European public assessment report (EPAR): Livogiva, teriparatide, Date of authorisation: 27/08/2020, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 10 December 2025 - 14:45
Human medicines European public assessment report (EPAR): Livogiva, teriparatide, Date of authorisation: 27/08/2020, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Kovaltry, octocog alfa, Date of authorisation: 18/02/2016, Revision: 15, Status: Authorised
Submitted by Anonymous (not verified) on 10 December 2025 - 14:40
Human medicines European public assessment report (EPAR): Kovaltry, octocog alfa, Date of authorisation: 18/02/2016, Revision: 15, Status: Authorised
Radiopharmaceuticals - Scientific guideline
Submitted by Anonymous (not verified) on 10 December 2025 - 14:30
Radiopharmaceuticals - Scientific guideline